Leflunomide and Pataday drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Leflunomide (leflunomide) and Pataday (olopatadine hydrochloride). Common drug interactions include influenza among females and diarrhoea among males.

The phase IV clinical study analyzes what interactions people have when they take Leflunomide and Pataday. It is created by eHealthMe based on reports of 32 people who take the same drugs from the FDA, and is updated regularly.

What is Leflunomide?

Leflunomide has active ingredients of leflunomide. It is often used in rheumatoid arthritis. eHealthMe is studying from 82,105 Leflunomide users. Check the latest studies of Leflunomide.

What is Pataday?

Pataday has active ingredients of olopatadine hydrochloride. It is often used in allergies. eHealthMe is studying from 8,288 Pataday users. Check the latest studies of Pataday.



On Jul, 19, 2026

32 people who take Leflunomide and Pataday together, and have interactions are studied.

Leflunomide and Pataday drug interactions.

What are the common drug interactions of Leflunomide and Pataday, by gender? *:

female:

  1. Influenza
  2. Urticaria (rash of round, red welts on the skin that itch intensely)
  3. Sinusitis (inflammation of sinus)
  4. Headache (pain in head)
  5. Leukopenia (less number of white blood cells in blood)
  6. Nausea (feeling of having an urge to vomit)
  7. Sjogren's syndrome (a disease that causes dryness in the mouth and eyes)
  8. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  9. Diarrhoea
  10. Infusion related reaction

male:

  1. Diarrhoea
  2. Asthenia (weakness)
  3. Headache (pain in head)
  4. Migraine (headache)
  5. Urinary tract infection
  6. Chills (felling of cold)
  7. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  8. Dry mouth
  9. Erectile dysfunction
  10. Libido decreased (loss of interest in sex)

What are the common drug interactions of Leflunomide and Pataday, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Influenza
  2. Sinusitis (inflammation of sinus)
  3. Urticaria (rash of round, red welts on the skin that itch intensely)
  4. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  5. Infusion related reaction

30-39:

n/a

40-49:

  1. Headache (pain in head)
  2. Leukopenia (less number of white blood cells in blood)
  3. Nausea (feeling of having an urge to vomit)
  4. Sjogren's syndrome (a disease that causes dryness in the mouth and eyes)

50-59:

  1. Asthenia (weakness)
  2. Cough
  3. Diarrhoea
  4. Dyspnoea (difficult or laboured respiration)
  5. Influenza
  6. Lung disorder (lung disease)
  7. Pancreatitis (inflammation of pancreas)
  8. Peripheral vascular disorder
  9. Productive cough
  10. Pulmonary embolism (blockage of the main artery of the lung)

60+:

  1. Diarrhoea
  2. Asthenia (weakness)
  3. Migraine (headache)
  4. Urinary tract infection
  5. Chills (felling of cold)
  6. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  7. Drug ineffective
  8. Fall
  9. Head injury
  10. Influenza

What are the existing conditions these people have? *

  1. Idiopathic Pulmonary Fibrosis (chronic lung disease): 5 people, 15.62%
  2. Pain: 4 people, 12.50%
  3. Itching: 4 people, 12.50%
  4. Migraine (headache): 3 people, 9.38%
  5. Interstitial Lung Disease: 3 people, 9.38%
  6. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 6.25%
  7. Asthma: 2 people, 6.25%
  8. Cardiac Disorder: 2 people, 6.25%
  9. Cough: 2 people, 6.25%
  10. Diabetes: 2 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Leflunomide and Pataday?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Leflunomide and Pataday:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Leflunomide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Pataday:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Leflunomide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pataday and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on leflunomide and olopatadine hydrochloride (the active ingredients of Leflunomide and Pataday, respectively), and Leflunomide and Pataday (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: